Skip to main content
. 2010 Feb;1(2):164–176. doi: 10.1177/1947601910362446

Figure 3.

Figure 3.

GSK-3β inhibitions attenuate the response of Ba/F3-FLT3-ITD cells to the FLT3 kinase inhibitors on cell proliferation in a Wnt/β-catenin pathway–dependent manner. (A) Stable expression of dnGSK-3β in Ba/F3-FLT3-ITD cells decreases the potencies of the FLT3 kinase inhibitors on proliferation. Ba/F3-FLT3-ITD cells stably expressing either empty vector or dnGSK-3β were treated with FLT3 kinase inhibitors for 68 to 72 h and then stained with trypan blue and counted under microscope, respectively. (B) Transient expression of GSK-3β siRNA in Ba/F3-FLT3-ITD cells also decreases the potency of the FLT3 kinase inhibitor on proliferation. The potency could be restored by transient expression of either the dominant negative form of TCF4 (dnTCF4) or antisense β-catenin (antiCat) in Ba/F3-FLT3-ITD cells stably expressing dnGSK-3β. The cells were electroporated with corresponding plasmid DNAs indicated. Twenty to 24 h after electroporation, cells were analyzed as in (A). (C) Expression levels of GSK-3β, TCF-4 (as detected by c-Myc tag), and β-catenin in transient assays. Cells were collected at the same time as transient assays in (B) and lysed in NP-40 lysis buffer. The whole-cell lysates were then subjected to immunoblotting analysis using antibodies indicated.